Infex Therapeutics and LifeArc announce collaboration to defeat superbugs

Infex Therapeutics has combined forces with medical research charity, LifeArc, to develop the next generation of drugs to treat serious infections caused by superbugs.

The collaboration will see Infex Therapeutics develop innovative antimicrobial compounds against LifeArc’s drug targets, in particular to tackle critical-priority Gram-negative bacteria.

Dr Peter Jackson, executive director of Infex Therapeutics, said, “We are delighted to announce this important collaboration with LifeArc, which could make a significant contribution to re-invigorating the pipeline of new products to treat drug-resistant infections.”

Katy Kettleborough, Head of Biology at LifeArc said “We are looking forward to working with Infex Therapeutics on our early discovery targets and value their expertise in this space”

It is anticipated that a number of disease targets will be progressed through the collaboration.